Core Viewpoint - The company reported a total revenue of HKD 4.1402 billion for the fiscal year ending March 31, 2025, reflecting a year-on-year decrease of 1.7% and a significant increase in shareholder losses to HKD 167.2 million from a loss of HKD 18.947 million in the previous year, indicating challenges in the market and operational efficiency [1][2] Financial Performance - Total revenue for the company was HKD 4.1402 billion, with sales slightly down by 1.0% to HKD 4.170 billion, attributed to cautious consumer spending in cross-border healthcare services and a strategic divestment of certain medical assets [1] - Adjusted EBITDA decreased by 15.1% to HKD 375.2 million, reflecting market challenges and strategic investments aimed at long-term operational efficiency [2]
医思健康(02138.HK)年度总收入达41.40亿港元 股东应占亏损扩大至1.67亿港元